Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma
“Initiating enrollment in this study is an important milestone for Aminex and for patients facing advanced cancers with limited treatment options,” said Mark Burns, PhD, Chief Scientific Officer and President of Aminex. “This trial builds on our foundation of pre- and early clinical data demonstrating the potential of AMXT 1501 plus DFMO to block the polyamine metabolism—a pathway that drives tumor growth and suppresses immune responses. We are advancing this program, in collaboration with leading adult oncology investigators and pediatric oncologists, targeting eight aggressive solid tumor types.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the